GoldenGolden
Advanced Search
Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics is a biotechnology and pharmaceutical company developing therapeutics for Alzheimer’s disease and other neurodegenerative disorders that is headquartered in Pittsburgh, Pennsylvania in 2007 by Gilbert Rishton and Susan Catalano.

Cognition Therapeutics is a biotechnology and pharmaceutical company that was founded by Gilbert Rishton and Susan Catalano in 2007, and is headquartered in Pittsburgh, Pennsylvania.

Cognition Therapeutics engages in drug development and discovery to develop novel approaches to the treatment of central nervous system disorders. The companies treatment approach to central nervous system disorders, such as Alzheimers disease and other neurodegenerative disorders, is to prevent the accumulation of toxic proteins associated with central nervous system disorders through the discovery and application of small molecule drug therapies.

Cognition’s lead candidate product is Elayta, an orally available small molecule was shown in clinical studies to have potential to normalize protein trafficking and lipid metabolism pathways disrupted in Alzheimer’s disease and allow protection and restoration of synapses. As of 2019 three Phase 2 clinical studies testing Elayta were SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition), SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients), and SHINE (Synaptic Health and Improvement of Neurological Function with Elayta). These studies were supported by grants (award numbers RF1AG057780, RF1AG057553 and R01AG058660) from the National Institute on Aging of the NIH. Elayta was granted Fast Track designation by the U.S. FDA.

Timeline

September 13, 2013
Cognition Therapeutics raises a $3,000,000 series B round.
July 15, 2009
Cognition Therapeutics raises a $1,210,000 series A round from Innovation Works and Pittsburgh Life Sciences Greenhouse.
2007
Cognition Therapeutics was founded by Gilbert M. Rishton and Susan Catalano.

Funding rounds

People

Further reading

Documentaries, videos and podcasts

Companies

News

Title
Author
Date
Publisher
Description
BioSpace
April 20, 2021
BioSpace
Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage response pathways, announced that the board of directors has elected Jack A. Khattar chairman of the board. Mr. Khattar, the founder and CEO of Supernus Pharmaceuticals, was appointed in 2020 to serve as a member of the Cognition board of directors. He replaces former chairman, Robert J. Gailus, w
BioSpace
June 8, 2020
BioSpace
Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer's disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in indi

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.